The High Throughput Screening Facility (HTSF) has developed during the previous five years to meet a need identified for high throughput capabilities and a central resource for multiple areas of translational research. The HTSF provides screening services, including the instrumentation and expertise to develop assays, execute siRNA and small molecule screens, and support for follow-up and secondary assay development and execution. In addition, the HTSF resources are available to clinical investigators to develop and implement clinical correlate assays for clinical trials and population science studies. The automation and detection instrumentation is available to all Fox Chase Cancer Center (FGGG) researchers, providing new technologies to investigators. Instrumentation and resources available from the HTSF include: automation compatible with 96 and 384 well screening platforms, the human genome siRNA library (Thermo-Fisher Dharmacon), and small molecule libraries (approx 50,000 compounds). Duhng its period as a developing facility the HTSF has acquired resources and reagents, initiated procedures for screen execution and provided assay services and screening support. In GY 2009, the HTSF provided support to 19 peer-reviewed, funded investigators, from all five of the Center's CCSG Research Programs (Section V). This user base has developed due to the strong institutional support provided by FCCC, including $776,808 for start-up equipment, as well as $1,454,952 in operating costs (FY2005-present). This has enabled the Facility to charge back Principal Investigators, (Pis) at reduced rates to enhance usage. The combination of equipment, expertise and subsidization has converged to create a community of screeners and translational scientists by initiating collaborative relationships among PI laboratories as well as between facilities, while in the process creating additional demand for HTSF support. The HTSF is a unique resource, as it combines services to a diverse group of investigators and collaboration among multiple, facilities. This allows the HTSF to act as a hub for translational science by making the most of the Center's resources in high throughput technology, traditional benchwork and clinical approaches.
The HTSF provides a suite of services designed to accelerate the identification of new tools and therapeutic targets for cancer. Discoveries made through utilization of the screening and assay development tools provided by the HTSF will impact areas such as development of innovative probes for basic research, biomarker discovery and novel therapeutic approaches.
|Boland, Patrick M; Meyer, Joshua E; Berger, Adam C et al. (2016) Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol :|
|Heckman, Carolyn J; Handorf, Elizabeth A; Darlow, Susan D et al. (2016) An Online Skin Cancer Risk-Reduction Intervention for Young Adults: Mechanisms of Effects. Health Psychol :|
|Meropol, Neal J; Wong, Yu-Ning; Albrecht, Terrance et al. (2016) Randomized Trial of a Web-Based Intervention to Address Barriers to Clinical Trials. J Clin Oncol 34:469-78|
|Hayakawa, K; Formica, A M; Colombo, M J et al. (2016) Loss of a chromosomal region with synteny to human 13q14 occurs in mouse chronic lymphocytic leukemia that originates from early-generated B-1 B cells. Leukemia 30:1510-9|
|Tan, Yinfei; Xin, Xiaoban; Coffey, Francis J et al. (2016) Appl1 and Appl2 are Expendable for Mouse Development But Are Essential for HGF-Induced Akt Activation and Migration in Mouse Embryonic Fibroblasts. J Cell Physiol 231:1142-50|
|Duong-Ly, Krisna C; Devarajan, Karthik; Liang, Shuguang et al. (2016) Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases. Cell Rep 14:772-81|
|Meeker, Caitlin R; Geynisman, Daniel M; Egleston, Brian L et al. (2016) Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer. J Oncol Pract 12:e755-64|
|Geynisman, Daniel M; Handorf, Elizabeth; Wong, Yu-Ning et al. (2016) Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer Med 5:192-9|
|Kurimchak, Alison M; Shelton, Claude; Duncan, Kelly E et al. (2016) Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Rep 16:1273-86|
|Borczuk, Alain C; Pei, Jianming; Taub, Robert N et al. (2016) Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biol Ther 17:328-35|
Showing the most recent 10 out of 884 publications